Jaguar and Land Rover carmaker pauses shipments to US over Trump tariffs
Jaguar Land Rover Automotive, one of the largest UK automakers, described the move as a 'short-term action' and said it would take the time to develop a longer-term plan to accommodate the new economic landscape.
'The USA is an important market for JLR's luxury brands,' the automaker said in a statement sent to media outlets.
'As we work to address the new trading terms with our business partners, we are taking some short-term actions including a shipment pause in April, as we develop our mid- to longer-term plans.'
Last month, Trump announced 25-percent tariffs on imported cars and light trucks, and the tariffs took effect on April 3, a day after the U.S. president announced his sweeping tariffs on dozens of other countries worldwide.
The U.S. imports 20 percent of British-made cars — according to Reuters, which cited data from the Society of Motor Manufacturers & Traders (SMMT) — making it the second-biggest importer after the European Union.
Some UK automakers started building stockpiles in the U.S. to mitigate the effects of Trump's tariffs, according to The Associated Press, which cited data showing exports to the U.S. increasing from the previous year by 38.5 percent in December, 12.4 percent in January, and 34.6 percent in February.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
26 minutes ago
- The Hill
Japan's SoftBank to take $2 billion stake in computer chip maker Intel
BANGKOK (AP) — Japanese technology giant SoftBank Group plans to take a $2 billion stake in computer chip maker Intel as it deepens its involvement in U.S. semiconductor manufacturing and other advanced technology in the United States, the companies said Monday. Shares in SoftBank fell 4% Tuesday in Tokyo following the announcement, which coincided with unconfirmed reports that President Donald Trump is considering having the U.S. government buy a stake in the chip maker. SoftBank invests in an array of companies that it sees as holding long-term potential. It has been stepping up investments in the United States since Trump returned to the White House. In February, its chairman Masayoshi Son joined Trump, Sam Altman of OpenAI and Larry Ellison of Oracle in announcing a major investment of up to $500 billion in a project to develop artificial intelligence called Stargate. SoftBank plans to buy $2 billion of Intel's common stock, paying $23 per share. That would be about a 2% stake. Intel's shares closed at $23.66 on Monday. 'Semiconductors are the foundation of every industry, Son said in a statement. 'This strategic investment reflects our belief that advanced semiconductor manufacturing and supply will further expand in the United States, with Intel playing a critical role.' SoftBank posted its first profit in four years in the April-June quarter as it raked in gains from its investment portfolios. It is a major shareholder in Arm Holdings, a British semiconductor and software design company. Intel helped launch Silicon Valley but has fallen behind rivals like Nvidia Corp. and Advanced Micro Devices Inc. and is shedding thousands of workers and slashing costs under its new CEO, Lip-Bu Tan. In the last quarter, the company reported a loss of $2.9 billion. Intel plans to end the year with 75,000 'core' workers excluding subsidiaries, through layoffs and attrition, down from 99,500 core employees at the end of 2024. The company previously announced a 15% workforce reduction. Trump recently said Tan, who was made CEO in March, should resign. But after meeting with him last week Trump relented, saying Tan had an 'amazing story.'
Business Insider
2 hours ago
- Business Insider
Analysts Rally Behind Eli Lilly (LLY) Stock After 24% Slide
Over the past year, Eli Lilly (LLY) stock has tumbled almost 24%, pressured by regulatory concerns, disappointing trial results, and broader market volatility. Yet beneath the selloff, Lilly's fundamentals remain strong, with recent results underscoring the company's resilience. Following this pullback, the stock's valuation looks increasingly attractive relative to its medium-term growth potential—suggesting a potential opportunity for long-term value investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. I remain Bullish on LLY stock with recent declines toward $700 serving as a decent opportunity to establish a long-term position. Why the Pressure on Lilly's Stock? To be fair, the recent slide in Eli Lilly's stock isn't just a random blip. Investors are spooked by a few things. First, there's the regulatory cloud hanging over the pharma industry as a whole due to President Trump's push for lower drug prices, including his 'most favored nation' policy to tie U.S. drug costs to cheaper international prices, which has folks worried about profit margins. Lilly's CEO, Dave Ricks, even called out the U.S. system's inefficiencies, like high consumer costs and red tape, which could get messier with new policies. Then there's the disappointment from the orforglipron trial; Lilly's experimental obesity pill showed an average weight loss of 12.4%, solid but below Wall Street's lofty estimates, sparking another subsequent sell-off on Aug. 7th. Add in broader market volatility, and it's no wonder investors are hitting the sell button. Discussions among investors are centering on whether Lilly's blockbuster drugs, Mounjaro and Zepbound, can sustain their momentum. The incretin market, where these drugs dominate, is getting crowded, and there's chatter about potential supply chain hiccups or market saturation. Nonetheless, these concerns might be overshadowing the bigger picture. Eli Lilly is Still a Rocketship Despite the gloom, Lilly's Q2 earnings crushed market expectations. On August 7th, the pharma giant posted revenue of $15.56 billion, up 38% year-over-year, blowing past Wall Street's $14.71 billion estimate. Earnings per share hit $6.31, a 61% jump from last year, beating forecasts by 12.48%. Mounjaro and Zepbound once again stole the spotlight, with Mounjaro raking in $5.2 billion (up 68%), while Zepbound brought in $3.38 billion (up 172%). These drugs are fueling Lilly's dominance in the diabetes and weight loss markets, with Mounjaro even snagging the top spot in U.S. prescriptions for type 2 diabetes incretins. Other highlights included Lilly's gross margin, which rose to 85%, up 3 points, thanks to better production costs and a favorable product mix. Then you have management investing heavily, with R&D expenses up 23% to $3.34 billion. I think this clearly shows confidence in Lilly's pipeline, and judging by the superb returns on invested capital the company has seen historically, I see this as great news. To top it all off, Lilly raised its full-year revenue guidance to $60–62 billion and EPS to $21.75–$23.00, reflecting strength across its portfolio, including some new launches like Kisunla and acquisitions like SiteOne Therapeutics for non-opioid pain treatments. As LLY CEO Dave Ricks put it in recent commentary to the market: 'Lilly is rolling,' and the numbers back that up. Is Eli Lilly a Hidden Gem? Eli Lilly's stock has always carried a premium, and for good reason. Growth rates have been off the charts, with its forward P/E ratio hovering between 40x and 60x in recent years. But following the recent 24% drop, things are looking different. At around $700 per share, Lilly stock is trading at about 30x this year's expected EPS of about $23. That's not exactly dirt-cheap, but for a company with a projected EPS growth rate of 32% annually over the next five years, it's starting to feel like a bargain. Compare that to the S&P 500's average P/E of around 25, which comes with much inferior EPS growth estimates, and Lilly's premium looks justified given its 30% expected growth trajectory. The company's 15% revenue CAGR over the past five years and 80%+ gross profit margin show fantastic scale dynamics, and the momentum has hardly slowed down. Sure, there's risk, including potential regulatory changes or trial setbacks that could sting, but the current price seems to bake in a lot of that worry already. If we compare LLY's performance against broader U.S. benchmarks like the S&P 500 (SPX), LLY is maintaining a premium despite suffering over the past twelve months. What is the 12-Month Forecast for LLY Stock? There are 22 analysts offering price targets on LLY stock through TipRanks, with an overwhelmingly bullish consensus. Today, the stock carries a Strong Buy consensus rating based on 17 Buy and five Hold ratings over the past three months. LLY's average stock price target of $924.42 suggests ~31% upside over the next twelve months. LLY's Pullback is an Opportunity, Not a Trap Lilly's selloff looks more like an overreaction than a reflection of its true strength. Yes, regulatory noise, trial hiccups, and crowded competition have rattled investors, but the company's financial performance and growth runway remain hard to ignore. With Mounjaro and Zepbound fueling monster revenue gains, a strong pipeline, and raised guidance, Lilly still looks like one of the most potent growth stories in pharma. This is why, at current levels, I believe the stock feels less like a trap and more like an opportunity.
Business Insider
2 hours ago
- Business Insider
Walmart (WMT) Counters Chinese Tariffs With New Ho Chi Minh Supply Route
Walmart (WMT) has made its latest move to combat President Trump's tariffs by allowing its marketplace sellers to ship directly from Vietnam to the U.S. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The U.S. retail giant said it was extending its cross-border ocean freight service beyond China by opening two Vietnamese ports to its marketplace sellers looking to ship full-container loads. Vietnamese Ports Sellers who source or manufacture goods in Vietnam can now book full-container shipments from Ho Chi Minh City or Hai Phong, with inventory transported directly to Walmart Fulfilment Services (WFS) facilities across the U.S. Sellers prepare full-container loads at either a Vietnamese or Chinese port, clear U.S. customs and then hand over the rest to Walmart's logistics network. Walmart's existing international freight network included Shanghai, Ningbo, Yantian, Qingdao and Xiamen in China. It has helped the retailer deliver consistently strong recent international sales. The move comes amidst Trump's tariff trade war which has seen the U.S. impose huge levies on countries importing goods into the States. Tariff Turmoil In July the U.S. and Vietnam secured a trade deal where Vietnamese goods exported to the U.S. will be charged at a baseline rate of 20% while products that experience transshipment will incur a 40% tariff. Transshipment occurs when a product is made in Country A and is then shipped to Country B before arriving in Country C in an attempt to escape duties. Trump likely requested a 40% tariff on transshipped items in order to stop the flow of Chinese goods into Vietnam and then the U.S. Chinese imports face a levy of 55% at present, which means that sellers have been looking for alternatives. Walmart has taken a knock from the new tariff regime, having to hike prices on certain goods. To what extent this and higher inflation have hit consumer confidence and spending will become apparent when Walmart releases its Q2 earnings later this week. Wall Street is expecting WMT to report earnings of $0.72 per share, which would represent year-over-year growth of 7.46%. Revenues for the period are expected to come in at $175.51 billion, up 3.65% from the prior-year quarter. Is WMT a Good Stock to Buy Now? On TipRanks, WMT has a Strong Buy consensus based on 23 Buy ratings. Its highest price target is $130. WMT stock's consensus price target is $113.86, implying a 13.23% upside.
